Endocannabinoids are marijuana-like compounds that are produced by most animals, including all vertebrates. Quite surprisingly, the endocannabinoids system has an all-pervasive role in maintaining homeostasis (biochemical balance). All living creatures suffer from a common biochemical imbalance, we are all aging. Today, in developed countries, most people suffer and die from age-related illnesses including cardiovascular diseases, autoimmune diseases, neurological disorders, and cancers. Modern science from an abundance of peer-reviewed publications indicates that stimulating the endocannabinoid system benefits all of these conditions.We understand what patients need and want. As a result, the Company offers the savvy investor a novel opportunity to participate in producing groundbreaking products that will impact some of the most important medical concerns of our times. In addition to targeting the billion dollars a year pain management industry, the Company is uniquely positioned to develop products for high blood pressure, cancer, HIV, and the bird flu.
Cannabis Science™ is in a unique position to pursue the development of blood pressure and cancer medications. The endocannabinoid system normally regulates blood pressure through its capacity to dilate blood vessels and reduce adrenergic stimuli. Additionally, there is a developing body of evidence that shows both the tumor killing properties of endo- and phyto- cannabinoids, and their ability to inhibit metastasis in a variety of cancers.
Cannabis Science™ works with world authorities on phytocannabinoid science developing cannabis-based therapeutics that will holistically promote health by restoring biochemical balance. By adhering to underlying scientific principles, the Company will manipulate all-pervasive phytocannabinoid processes to target a variety of disparate illnesses.
An emergent global threat is that the bird flu, a strain (H5N1) of influenza A, will evolve to infect human beings. The typical yearly variation in flu strains has been an ongoing challenge and concern to researchers developing preventative and therapeutic products. The high degree of variability found in the influenza A virus is an intrinsic property of the virus's chromosomal structure and how it replicates. Overcoming the difficulties encountered in this field take on even greater importance with the threat of the bird flu jumping species bird into the human population.
The bird flu differs from other strains by its enhanced capacity to kill infected individuals. The common cause of death with this strain is that patients developed adult respiratory distress syndrome (ARDS). ARDS is in excess inflammatory response that leads to apoptosis and organ failure. The Company's approach will mimic how the human body uses endocannabinoids to regulate immune activity and cell survival.
The magnitude of the bird flu threat is so great that positive results from this arm of our research would greatly facilitate the acceptance of our cannabis-based pharmaceuticals. There should be highly profitable additional applications that result.
More recently, revolutionary scientific breakthroughs in understanding the HIV infective and developmental processes have been discovered that will lead to entirely new therapeutic approaches.
Cannabis Science™ is uniquely positioned to explore insights that indicate an intrinsic link between novel cancer and HIV technologies and the cannabinoid system. Published experiments by a leading AIDS researcher, Dr. Donald Abrams, suggest that counter to conventional wisdom, smoked marijuana does not result in an increased HIV viral load. In fact, there were suggestions of a reduced viral load. We expect to show that our pharmaceuticals will enhance biochemical markers that are indicative of a successful HIV therapy based on recent paradigm breaking discoveries.
Overall, our product development will follow two parallel paths. We will create pharmaceuticals with and without psychoactive properties. Both of these lines will have numerous health benefits for treating illnesses and for general health maintenance. Both psycho and non-psychoactive products with demonstrated therapeutic efficacy for these globally important illnesses will facilitate entry first into the Canadian marketplace. Proven efficacy in the Canadian market should then open the US and global markets.
